KI I

Karolinska Institutet I, Stockholm, Sweden

Group Description

Brief description of legal entity
The Karolinska Institutet (KI) is one of the top Medical Universities in Europe. In 2010 KI celebrated the 200 year anniversary. KI is devoted to both Education, hosting the largest Faculty of Medicine in Sweden, and to Research. Neuroscience is one of the Research areas of Excellence at KI, with several Research Centres such as Stockholm Brain Institute, Stockholm Brain Power, and Ageing Research Centre, actively involved in the Neuroscience field. The KI-PET Centre belongs to the Department of Clinical Neuroscience and its Research activity is within the Centre for Psychiatry Research, belonging to the Stockholm County.

Main tasks
The KI-PET Centre has pioneered the field of molecular imaging of the CNS with PET since the early ´80s. Main expertise of the group is development of new radioligands for neuroreceptor imaging, and drug development programmes in collaboration with major pharmaceutical companies. At an applied level the group is actively involved in research projects in psychiatry (schizophrenia, social phobia, mood disorders, ADHD), neurodegenerative disorders (Alzheimer´s and Parkinson´s disease), epilepsy, pain, stroke, and neuroinflammation. Recent major advances in radioligand developments are synthesis and application of tracers for amyloid imaging ([11C]AZD2184 and [18F]AZ4694) and serotonin 5-HT1B receptors ([11C]AZ10419369).

Participation in INMiND:  WP3 / WP5 / WP7 / WP8 .

Previous experience relevant to INMiND tasks

The PET Centre is formed by approximately 60 people with competence in radiochemistry, psychiatry, neurology, nuclear medicine, computer science, psychology. Expertise covers different areas from radioligand development through ex vivo biological essays to post-mortem autoradiography, and to application in small animals, non-human primates and human subjects, including an advanced platform for image, data analysis and receptor quantification. Different [11C]- and [18F]-tracers for TSPO/PBR have been evaluated in Alzheimer´s disease and Multiple Sclerosis, including [11C]PK11195. The group is currently setting up the radiosynthesis of [11C]PBR28 for different application within CNS. The high-resolution research tomography (HRRT) is operating on a daily basis since Jan 2008. Christer Halldin, Balázs Gulyás and Andrea Varrone have contributed to WP3 (radioligand development) and WP8.2 and WP9 (neurodegenerative disorders) in FP6 NoE DiMI.


Karolinska Institute
Prof Christer HALLDIN
INMiND Office
European Institute for Molecular Imaging (EIMI) Waldeyerstr. 15
· 48149 Münster
Tel: +49 251 83 49300 · Fax: +49 251 83 49313
E-Mail: